UBS Group
GPCR icon

UBS Group’s Structure Therapeutics GPCR Stock Holding History

UBS Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Buy
378,986
+166,067
+78% +$7.35M ﹤0.01% 2658
2026
Q1 		$10.3M Buy
212,919
+10,442
+5% +$715K ﹤0.01% 3320
2025
Q4 		$14.1M Sell
202,477
-5,615
-3% -$229K ﹤0.01% 2937
2025
Q3 		$5.83M Buy
208,092
+55,111
+36% +$1.1M ﹤0.01% 3883
2025
Q2 		$3.17M Sell
152,981
-85,216
-36% -$1.87M ﹤0.01% 4340
2025
Q1 		$4.12M Sell
238,197
-5,866
-2% -$144K ﹤0.01% 3986
2024
Q4 		$6.62M Buy
244,063
+204,983
+525% +$7.27M ﹤0.01% 3519
2024
Q3 		$1.72M Buy
39,080
+33,717
+629% +$1.3M ﹤0.01% 4149
2024
Q2 		$211K Sell
5,363
-77,351
-94% -$3.18M ﹤0.01% 5624
2024
Q1 		$3.55M Buy
82,714
+23,077
+39% +$973K ﹤0.01% 3345
2023
Q4 		$2.43M Buy
+59,637
New +$3.42M ﹤0.01% 3596
2023
Q3 		– Sell
-2
Closed -$83 – 9646
2023
Q2 		$83 Buy
+2
New +$56 ﹤0.01% 8536

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

UBS Group's GPCR Position: Q2 2026 in Review

UBS Group increased its Structure Therapeutics (GPCR) stake by 78% in Q2 2026, buying an estimated $7.35M and bringing the position to 378,986 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2658.

UBS Group first reported a position in GPCR in Q2 2023 and has held it in 12 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • UBS Group held 378,986 shares of Structure Therapeutics worth $20.3M as of Q2 2026.
  • UBS Group bought 166,067 Structure Therapeutics shares in Q2 2026, an estimated $7.35M.
  • Structure Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2658 holding.
  • UBS Group first reported a position in Structure Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.